- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sonia T. Oskouei, PharmD: Biosimilars and Misinformation
Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses biosimilars and misinformation.
Transcript
So, it is hard to manage all of the information that’s out there. Understandably, there’s a lot of different data sources and sites where you can get information, so to manage it all alone is a challenge. But there’s different information out there that talks about aspects of biosimilars, from interchangeability to extrapolation. When it’s out there, it could cause a misunderstanding about biosimilars, whether it’s intentional or not. So that’s, again, the need for education from a patient and provider level to help clarify any of those aspects with biosimilars.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
